Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Nitec Pharma expands senior management team


Basel, Switzerland, 04 October 2007 – Nitec Pharma AG, today announced a substantial expansion of its management team. Nitec appointed Dr. Stephan Witte, as Chief Medical Officer and Head of Global Clinical Development, Dr. Michael Lüttgen as Vice President Marketing & Sales, Dr Hans Rensland as Vice President Regulatory Affairs, Dr. Rainer Rogasch as Vice President Technical Operations & Development, Dr. Markus Vogt as Vice President of Quality and Compliance and James Audibert as Vice President Commercial Optimization.

'We are excited to be expanding the Nitec team, with all five candidates having exceptional leadership capabilities and pharmaceutical experience,' said Anders Härfstrand the CEO of Nitec. 'Their track record in successfully leading companies to the forefront of the industry is outstanding, and we are confident in their abilities to help taking Nitec forward as a successful specialty biopharmaceutical company”

Dr. Stephan Witte, the Chief Medical Officer and Head of Global Clinical Development, has more than 10 years experience in biomedical research and clinical development. Before joining Nitec Pharma, he held a variety of positions with Altana Pharma AG, Quintiles and ICON Clinical Research. His experience includes design and operative management of global clinical development programs and clinical studies in the indications asthma and COPD. Dr. Witte holds a M.S. in Chemistry and completed a PhD thesis at the University of Konstanz. Subsequently he underwent post-doctoral training at the La Jolla Institute for Allergy and Immunology in San Diego and completed post-graduate training in pharmaceutical medicine at the ECPM in Basel.

Dr. Michael Lüttgen, Vice President Marketing & Sales at Nitec, held senior marketing positions in Mayne Pharma, Cephalon and Baxter Germany during the last four years. At Baxter, he was Marketing Director for Renal Therapies in Germany. His career in the pharmaceutical industry began at Merck KGaA, as sales representative from 1992 to 1995 and the product manager for corticosteroids from 1995 to 1997. Dr. Lüttgen originally studied Biology at the JWG University, Frankfurt/M, where he was also awarded a PhD in1993.

Dr. Hans Rensland, Vice President Regulatory Affairs at Nitec, was for the last four years the Director of Regulatory Affairs at Biologische Heilmittel Heel GmbH. Previous to this, he has held senior positions in Regulatory Affairs in a variety of international acting companies including Merck KGaA, Knoll AG, and Intersan GmbH. Dr. Rensland completed his PhD in oncology at the Max Planck Institute for Medical Research in Heidelberg in 1992.

Dr. Rainer Rogasch will work as Vice President Technical Operations & Development and was previously General Manager and Technical Director at Madaus GmbH. Before, Dr. Rogasch was Head of Production and Development at alphamed Pharbil/PenCef GmbH. Dr. Rogasch also worked in Pharmacy Management after graduating with a PhD in pharmaceutical technology as Pharmacist from the Philipps-University Marburg/Lahn, Germany.

Dr Markus Vogt, Vice President of Quality and Compliance, was formerly Head of Technical Development at Nitec Pharma. Previous to this, Dr Vogt held a variety of positions in pharmaceutical development at Merck KGaA. He received his PhD in pharmaceutical technology from the University of Frankfurt during this period. He originally studied pharmacy at Johannes Gutenberg-Universität, Mainz, and completed the State Exams in pharmacy in 2001.

James Audibert (based in New Jersey/US), Vice President Commercial Optimization, has over 30 years of experience in the pharmaceutical industry. Most of his career was spent with Key Pharmaceuticals and Schering Plough (SP) where he was involved in US sales and marketing, managed care, global marketing, and research. From 1995 to 2000, he was responsible for SP’s Global Marketing Cardiovascular Business Unit, and then moved to the Schering Plough Research Institute, wh


Publisher Contact Information:

Nitec Pharma AG
+41 61 715 20 46
anders.harfstrand@nitecpharma.com

Company profile of Nitec Pharma AG
Past press releases of Nitec Pharma AG.

Data


26,227
Tech investments
From our Online Data Service
16,943
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.